GeoVax Sponsors Global Health Equity Summit to Advance Vaccine Access

GeoVax, Inc., a clinical-stage biotechnology company trading on Nasdaq as GOVX, has announced its sponsorship of the 3rd Annual Dr. David Satcher Global Health Equity Summit hosted by Morehouse School of Medicine in Atlanta, Georgia. The summit, taking place on October 2, 2025, brings together global health experts, policymakers, researchers, and community organizations under the theme "The Quest for Health Equity & Justice: A Glocal Perspective." This gathering focuses on scaling local innovations and partnerships to address global healthcare disparities, with keynote speaker Dr. John N. Nkengasong, the U.S. Global AIDS Coordinator, leading distinguished discussions on vaccine access, pandemic preparedness, and community-driven health equity models. Summit details here provide comprehensive information about this critical global health initiative.

Representing GeoVax at the event is Dr. Mary Hauser, Director of Preclinical Research, who will showcase the company's innovative MVA-based vaccines designed specifically for immunocompromised and underserved populations. GeoVax's commitment extends beyond sponsorship to active participation in advancing solutions that ensure lifesaving vaccines reach those most in need. The company's Chairman and CEO, David Dodd, emphasized that "health equity is not just a goal - it is a mandate for global progress," highlighting their partnership with Morehouse School of Medicine as a strategic alignment with their corporate mission. The summit honors Dr. David Satcher, the 16th Surgeon General of the United States, and serves as a catalyst for sustainable change through research, innovation, and policy collaboration.

GeoVax's portfolio includes GEO-CM04S1, a next-generation COVID-19 vaccine currently in three Phase 2 clinical trials targeting immunocompromised patients, chronic lymphocytic leukemia patients, and healthy individuals seeking more robust protection. The company is also advancing Gedeptin®, an oncolytic solid tumor therapy for head and neck cancers, and anticipates progressing directly to Phase 3 trials for their Mpox and smallpox vaccine following recent EMA regulatory guidance. With worldwide rights to their technologies and a strong intellectual property portfolio, GeoVax maintains its commitment to developing multi-antigen vaccines and immunotherapies that address critical healthcare gaps. For more information about their clinical trials and technological advancements, visit www.geovax.com to stay updated on their progress in transforming global health outcomes through equitable access to medical innovation.